The estimated and theoretical assurances and the probabilities of launching a phase III trial

MaRDI QIDQ5086970zbMATH OpenFDO

Authors Ying-Ying Zhang, Tengzhong Rong, Manman Li

Publication date 8 July 2022

Full work available at URL http://aps.ecnu.edu.cn/EN/abstract/abstract9445.shtml

zbMATH Keywords

assurancego/no go decisionlaunch criterionphase II/III clinical trialprobability of success (POS)

Mathematics Subject Classification ID

Parametric hypothesis testing (62F03) Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Theory of drug development
• Approximately optimal designs for phase II clinical studies
• Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed
• Randomized phase III oncology trials: a survey and empirical Bayes inference
• Practical Bayesian Guidelines for Phase IIB Clinical Trials

Cited in

(1)

• Randomized phase III oncology trials: a survey and empirical Bayes inference

This page was built for publication: The estimated and theoretical assurances and the probabilities of launching a phase III trial

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5086970)